Last close As at 18/09/2026
GBP2.79
— 0.00 (0.00%)
Market capitalisation
GBP196m
Content on this client is only available to investors based in the UK.
Please use the tick box below to confirm your location.
Investment Companies
Investment Companies
Research: Investment Companies
HBM Healthcare Investments (HBMN) posted its first NAV loss in a decade for FY22 (ended 31 March), but, as shown in the chart below, its long-term performance record remains very impressive. The recent fall in the share price from a premium to a discount to NAV (10.0% at 20 May) could present an opportunity for long-term investors who, like HBMN’s management team, remain convinced of the long-term opportunities afforded by careful investment in the healthcare and biotechnology space. HBMN is unusual among its peers in offering a portfolio made up of private companies, listed equities and funds, broadly spread by geography and clinical focus, with a high distribution policy (current yield of 3.8%).